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A 72-year-old male with a previous medical history consistent with chronic systolic heart failure 
presented for frequent episodes of generalized fatigue and shortness of air for the past week. The 
patient noted that his symptoms started a few days after he began a new anti-fungal medication. 
The initial echocardiogram is shown below. 
 
 
 
 
 
What is the most likely diagnosis? 
 
A) Long QT syndrome 
B) Digoxin toxicity 
C) Sick sinus syndrome 
D) Hypocalcemia 
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CORRECT ANSWER:  B 
The ECG revealed a narrow QRS complex rhythm at a rate of 78 beats/minute without 
clearly visualized P waves, consistent with accelerated junctional rhythm.  In the setting of 
chronic heart failure, this is often caused by digitalis toxicity.  Low voltage is evident in the limb 
leads (QRS amplitude < 5 mm) which may be due to pleural effusion, pericardial effusion, or 
restrictive, infiltrative, or severe ischemic cardiomyopathy.  Further questioning revealed this 
patient was on digoxin therapy and recently started anti-fungal therapy.  His diuretic regimen 
increased which most likely led to his digoxin toxicity. 
 
Discussion 
Digoxin is a complex agent in that its mode of action, inhibition of sodium-potassium 
adenosine triphosphatase, affects multiple cellular processes, including several critical to cardiac 
myocyte function.1  Digoxin also is extremely toxic, not surprising in view of its apparent role in 
nature as a toxin evolved by plants to kill mammals.  Digoxin has a low therapeutic index and it 
should be monitored carefully by serum blood levels.  The various clinical conditions and drug 
interactions that can alter digoxin's pharmacokinetics also are reflected in the serum digoxin 
level.  The optimal trough digoxin serum level is 0.5 to 1.0 ng/mL.  In patients with heart failure, 
overt clinical toxicity tends to emerge at serum concentrations greater than 2.0 ng/mL, but 
substantial overlap in serum levels exists among patients exhibiting symptoms and signs of 
toxicity and those with no clinical evidence of intoxication.  
Disturbances in cardiac impulse formation, conduction, or both are the hallmarks of digitalis 
toxicity.2 Among the common electrocardiographic manifestations are ectopic beats of AV 
junctional or ventricular origin, first-degree AV block, an excessively slow ventricular rate 
response to atrial fibrillation, or an accelerated AV junctional pacemaker.  These manifestations 
may require only dosage adjustment and monitoring.  Sinus bradycardia, sinoatrial arrest or exit 
block, and second- or third-degree AV conduction delay often respond to atropine, but temporary 
ventricular pacing sometimes is necessary and should be available. Neurological or 
gastrointestinal complaints also can be manifestations of digitalis toxicity. Occasionally, 
gynecomastia results from digoxin administration, due to similarity with estrogen’s structure. 
Oral potassium administration often is useful for management of atrial, AV junctional, or 
ventricular ectopic rhythms, even when the serum potassium is in the normal range, unless high-
grade AV block also is present.1,2  However, potassium must be monitored carefully to avoid 
hyperkalemia, especially in patients with renal failure.  Magnesium may be useful in patients 
with atrial fibrillation in an accessory pathway in whom digoxin administration has facilitated a 
rapid accessory pathway-mediated ventricular response.1 Again, careful monitoring is required to 
avoid hypermagnesemia.  
Potentially life-threatening digoxin or digitoxin toxicity can be reversed by antidigoxin 
immunotherapy.1 Purified Fab fragments from digoxin-specific antisera are available at most 
poison control centers and larger hospitals in North America and Europe. Clinical experience in 
adults and children has established the effectiveness and safety of antidigoxin Fab in treating 
life-threatening digoxin toxicity, including cases of massive ingestion with suicidal intent. 
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